Stockreport

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization [Yahoo! Finance]

ARS Pharmaceuticals, Inc.  (SPRY) 
PDF Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million in cash, cash equivalents and short-term inve [Read more]